TY - JOUR
T1 - Therapeutics discovery
T2 - From bench to first in-human trials
AU - Al-Hujaily, Ensaf M.
AU - Khatlani, Tanvir
AU - Alehaideb, Zeyad
AU - Ali, Rizwan
AU - Almuzaini, Bader
AU - Alrfaei, Bahauddeen M.
AU - Iqbal, Jahangir
AU - Islam, Imadul
AU - Malik, Shuja
AU - Marwani, Bader A.
AU - Massadeh, Salam
AU - Muzaini, Bader
AU - Nehdi, Atef
AU - Alsomaie, Barrak
AU - Debasi, Bader
AU - Bushnak, Ibraheem
AU - Noibi, Saeed
AU - Hussain, Syed
AU - Wajid, Wahid Abdul
AU - Armand, Jean Pierre
AU - Gul, Sheraz
AU - Oyarzabal, Julen
AU - Rais, Rana
AU - Bountra, Chas
AU - Alaskar, Ahmed
AU - Al Knawy, Bander
AU - Boudjelal, Mohamed
N1 - Publisher Copyright:
© 2018, Spandidos Publications. All rights reserved.
PY - 2018/3
Y1 - 2018/3
N2 - The ‘Therapeutics discovery: From bench to first in-human trials’ conference, held at the King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard Health Affairs (MNGHA), Kingdom of Saudi Arabia (KSA) from October 10-12, 2017, provided a unique opportunity for experts worldwide to discuss advances in drug discovery and development, focusing on phase I clinical trials. It was the first event of its kind to be hosted at the new research center, which was constructed to boost drug discovery and development in the KSA in collaboration with institutions, such as the Academic Drug Discovery Consortium in the United States of America (USA), Structural Genomics Consortium of the University of Oxford in the United Kingdom (UK), and Institute of Materia Medica of the Chinese Academy of Medical Sciences in China. The program was divided into two parts. A pre-symposium day took place on October 10, during which courses were conducted on clinical trials, preclinical drug discovery, molecular biology and nanofiber research. The attendees had the opportunity for one-to-one meetings with international experts to exchange information and foster collaborations. In the second part of the conference, which took place on October 11 and 12, the clinical trials pipeline, design and recruitment of volunteers, and economic impact of clinical trials were discussed. The Saudi Food and Drug Administration presented the regulations governing clinical trials in the KSA. The process of preclinical drug discovery from small molecules, cellular and immunologic therapies, and approaches to identifying new targets were also presented. The recommendation of the conference was that researchers in the KSA must invest more fund, talents and infrastructure to lead the region in phase I clinical trials and preclinical drug discovery. Diseases affecting the local population, such as Middle East Respiratory Syndrome and resistant bacterial infections, represent the optimal starting point.
AB - The ‘Therapeutics discovery: From bench to first in-human trials’ conference, held at the King Abdullah International Medical Research Center (KAIMRC), Ministry of National Guard Health Affairs (MNGHA), Kingdom of Saudi Arabia (KSA) from October 10-12, 2017, provided a unique opportunity for experts worldwide to discuss advances in drug discovery and development, focusing on phase I clinical trials. It was the first event of its kind to be hosted at the new research center, which was constructed to boost drug discovery and development in the KSA in collaboration with institutions, such as the Academic Drug Discovery Consortium in the United States of America (USA), Structural Genomics Consortium of the University of Oxford in the United Kingdom (UK), and Institute of Materia Medica of the Chinese Academy of Medical Sciences in China. The program was divided into two parts. A pre-symposium day took place on October 10, during which courses were conducted on clinical trials, preclinical drug discovery, molecular biology and nanofiber research. The attendees had the opportunity for one-to-one meetings with international experts to exchange information and foster collaborations. In the second part of the conference, which took place on October 11 and 12, the clinical trials pipeline, design and recruitment of volunteers, and economic impact of clinical trials were discussed. The Saudi Food and Drug Administration presented the regulations governing clinical trials in the KSA. The process of preclinical drug discovery from small molecules, cellular and immunologic therapies, and approaches to identifying new targets were also presented. The recommendation of the conference was that researchers in the KSA must invest more fund, talents and infrastructure to lead the region in phase I clinical trials and preclinical drug discovery. Diseases affecting the local population, such as Middle East Respiratory Syndrome and resistant bacterial infections, represent the optimal starting point.
KW - CART
KW - Clinical trials
KW - Drug target
KW - KAIMRC
KW - MNGHA
KW - Phase I
UR - http://www.scopus.com/inward/record.url?scp=85041415644&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85041415644&partnerID=8YFLogxK
U2 - 10.3892/br.2018.1052
DO - 10.3892/br.2018.1052
M3 - Article
C2 - 29564125
AN - SCOPUS:85041415644
SN - 2049-9434
VL - 8
SP - 275
EP - 282
JO - Biomedical Reports
JF - Biomedical Reports
IS - 3
ER -